Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biora Therapeutics Inc

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biora Therapeutics excels in therapeutics programs, secures strategic partnerships

Biora Therapeutics demonstrated strong performance in key programs, maintained financial stability, and expressed confidence in future prospects.
While facing challenges in device performance and operational planning, the company is well-positioned to capitalize on opportunities for growth and innovation.
Overall, Biora's focus on advancing therapeutic programs and strategic collaborations signals a positive trajectory for the company's future success.

Biora Therapeutics reports stable finances, progresses key drug programs

Biora Therapeutics showcased solid financial management with increased operating expenses but a stable cash position, while also securing additional funding for growth.
The company's focus on key programs and strategic collaborations, coupled with the appointment of a new Chief Medical Officer, bodes well for its clinical development efforts.
Despite challenges in managing expenses and optimizing capital structure, Biora's promising results and strategic initiatives offer opportunities for future growth and success in the pharmaceutical industry.

Biora Therapeutics advances drug delivery platforms and maintains financial stability

Biora Therapeutics showcased progress on innovative drug delivery platforms in Q2 2023. The company's financials remain stable, with a focus on disciplined cash management. Securing partnerships and advancing regulatory filings are key focus areas for future growth.

Biora Therapeutics reduces debt, advances key platforms amid financial challenges

Biora Therapeutics demonstrated financial progress alongside operational advancements in its NaviCap and BioJet platforms, despite facing increased expenses and a net loss for the quarter.
The company's focus on FDA clearance for BT-600 trial initiation and collaborations for the BioJet platform highlights its commitment to advancing innovative therapies and partnerships.
While challenges persist in financial management and collaboration coordination, Biora Therapeutics remains poised to leverage opportunities for growth and market expansion in the biopharmaceutical sector.

Biora Therapeutics excels in Q4 2023 with innovative drug technologies

Biora Therapeutics made significant strides in Q4 2023, advancing their platform technologies and strengthening their financial position. While facing challenges in clinical trials and market competition, the company is well-positioned to capitalize on opportunities for growth and partnerships in the coming year.

Biora Therapeutics advances drug delivery platforms, strengthens financial position

Biora Therapeutics' Q1 performance reflects a strategic focus on R&D, financial strength, and advancements in targeted drug delivery platforms.
The company faces challenges in optimizing partnerships and capital structure while balancing innovation and financial sustainability.
Opportunities lie in upcoming data releases, clinical studies, and partnerships to drive growth and market expansion in 2024.

Biora Therapeutics excels in Q2 with breakthrough drug delivery platforms

Biora Therapeutics' innovative drug delivery platforms show promise in revolutionizing ulcerative colitis treatment and advancing JAK inhibitor therapy.
The company's successful Phase I trial results and capital raise provide a strong foundation for future growth and partnership opportunities.
While challenges lie ahead in scaling up and navigating the competitive landscape, Biora's focus on breakthrough technologies positions them well for success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date

Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform

SAN DIEGO, July 17, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company's management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern time / 1:30 PM Pacific time.

Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora's former diagnostics business.

Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets

SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.

Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform

An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced registered direct offering of an aggregate of 1,509,434 shares of the Company's common stock at an offering price of $5.30 per share of common stock and concurrent private placement of warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, are exercisable upon issuance, and will expire three years following the date of issuance.

Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company's common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.

Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Alzamend Neuro

PAVmed

Developing groundbreaking drugs and devices entails high costs, uncertain regulatory approval, and lucrative revenues. Those factors and more culminate to create a sector filled with dozens of biotech stocks that have 10X potential, or better.

3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Kristy Grabowski - IR Aditya Mohanty - CEO & Director Eric d'Esparbes - EVP & CFO Conference Call Participants Yuan Zhi - B. Riley Securities Matthew Keller - H.C.

Biora Therapeutics, Inc. (BIOR) Q1 2023 Earnings Call Transcript

Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets. The company's management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.

Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn's & Colitis, an event hosted by the Crohn's & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.

Biora Therapeutics to Participate in Crohn's & Colitis Foundation's IBD Innovate Conference

Biora Therapeutics, Inc. (NASDAQ:BIOR ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Chuck Padala – Managing Director-LifeSci Advisors Adi Mohanty – Chief Executive Officer Eric d'Esparbes – Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Sahil Kazmi – B. Riley Securities Operator Thank you for standing by.

Biora Therapeutics, Inc. (BIOR) Q4 2022 Earnings Call Transcript

Biora initiating preclinical testing with pharma collaborator's molecule following recent data exceeding the company's target bioavailability levels for systemic therapeutics platform

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022 financial results on Thursday, March 30, 2023 after the close of financial markets. The company's management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.

Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company's current target Preclinical data demonstrate potential to orally deliver peptides and monoclonal antibodies at bioavailability levels more than double the company's current target

Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist

Average bioavailability greater than 50% with high consistency observed in animal study Average bioavailability greater than 50% with high consistency observed in animal study

Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform

After losing some value lately, a hammer chart pattern has been formed for Biora Therapeutics, Inc. (BIOR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Aemetis

Blue Apron

Faraday Future Intelligent Electric

Gossamer Bio Inc

Pardes Biosciences

SmileDirectClub

Sientra

Tattooed Chef

Vroom

More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch With High Short Interest This Week

Short squeeze penny stocks to watch before February 2023. The post Penny Stocks To Buy: 5 Short Interest Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 5 Short Interest Stocks To Watch Now

Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administration

Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn's & Colitis Congress

Biora Therapeutics (NASDAQ: BIOR ) stock is on the rise Wednesday following news of feedback from the FDA. Today's news concerns the company's Targeted Therapeutics Platform and PGN-600 program for the treatment of ulcerative colitis (UC).

Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?

Biora Therapeutics Inc   (NASDAQ:BIOR) is looking to extend yesterday's pop, last seen up 8.5% at $5.86.

News for Biora Therapeutics Inc Stock (BIOR)